当前位置： SCI文献检索 > BMJ Open期刊下所有文献 > Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland.

Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland.

Abstract：

OBJECTIVE:To assess the representativeness of the Heart Protection Study (HPS) and the Collaborative Atorvastatin Diabetes Study (CARDS) for incident statin users. DESIGN:A population-based analysis with linked register data. SETTING:Finland. POPULATION:56 963 patients with diabetes initiating statin use from 2005 to 2008. MAIN OUTCOME MEASURES:We determined the proportions of real-world patients who fulfilled the eligibility criteria for HPS and CARDS trials and assessed the cardiovascular disease (CVD) event rates, assumed to reflect the background CVD risk, for those eligible and ineligible. We used descriptive statistics to identify the patient characteristics, lipid-lowering interventions and adherence to statin therapy. RESULTS:Of the real-world patients, 57% (N=32 582) fulfilled the eligibility criteria for HPS (DM) and 49% (N=20 499) of those without CVD for CARDS. The patients ineligible for HPS (DM) had a higher cumulative risk for CVD events than those eligible, whereas regarding CARDS the cumulative risks were of similar magnitude. The overall CVD event rates seemed to be comparable to those in the reviewed trials. Both trials were under-representative of women and users of antihypertensive agents and metformin. 27% and 29% of real-world patients had an initial statin dose corresponding to <20 mg of simvastatin. The proportions of patients who were deemed adherent were 57% in the real world and 85% in both trials. CONCLUSIONS:Only half of the real-world patients would have qualified for the HPS (DM) and CARDS, limiting their representativeness for clinical practice. Women and users of antihypertensive agents and metformin were under-represented in both trials. These deviations reflect the changes in diabetes treatment over the years and are not expected to modify the average treatment effects of statins on CVD. Prescribing of lower statin doses in clinical practice than used in the trials and lower adherence may, however, attenuate the benefits in the real world.

journal_name

BMJ Open

journal_title

BMJ open

authors

Ruokoniemi P,Sund R,Arffman M,Helin-Salmivaara A,Huupponen R,Keskimäki I,Vehko T,Korhonen MJ

doi

10.1136/bmjopen-2014-005402

subject

Has Abstract

pub_date

2014-06-19 00:00:00

pages

e005402

issue

6

issn

2044-6055

pii

bmjopen-2014-005402

journal_volume

4

pub_type

杂志文章

相关文献

BMJ Open文献大全